Precision oncology in adjuvant aspirin therapy for colorectal cancer: emerging genetic markers and persistent uncertainties
Genetic markers may help identify which colorectal cancer survivors benefit most from aspirin therapy, though evidence remains incomplete for clinical implementation.
This EBioMedicine commentary summarises genetic markers being investigated to identify CRC patients most likely to benefit from adjuvant aspirin—including PIK3CA mutation status and prostaglandin pathway markers—while acknowledging major uncertainties in trial evidence. The piece does not present new data but synthesises the current state of aspirin precision oncology in CRC.
What the study was
- Study design
- editorial_commentary
- Category
- precision_oncology
- Maturity
- Exploratory
- Journal
- EBioMedicine
Why it surfaced
Expert perspective on adjuvant aspirin biomarker stratification in CRC; low novelty and no original data but relevant to precision oncology topic. Score 3 (N=1, D=0, P=1, E=1) per conservative editorial/commentary cap.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.